BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 11, 2026
Home » Authors » Jim Stommen

Articles by Jim Stommen

The MDD Interview: Wellsense helping caregivers to ease patients' sore points

March 28, 2013
By Jim Stommen

Huge potential markets await Actium if new technology is okayed

March 21, 2013
By Jim Stommen

The MDD Interview: Investor has a more personal stake in cancer drug-delivery company

March 14, 2013
By Jim Stommen

Gigantic jury award in first J&J hip implant case is breathtaking as an initial benchmark

March 13, 2013
By Jim Stommen
Chilling. It isn’t often that a bit of news is a perfect fit to that one-word description, but the recent decision by a Los Angeles jury in the first case to be decided pitting Johnson & Johnson (J&J; New Brunswick, New Jersey) against what is a cast of thousands of litigants is nothing short of that. Oh sure, there’s the usual post-decision posturing by the company per appealing the $8.3 million-plus jury award, but c’mon folks, the implications of this case for the medical-products giant – and truly for all other companies trying to do business in the med-tech space...
Read More

The MDD Interview: 'Upstarts' push their way up list of life sciences centers

March 7, 2013
By Jim Stommen
Jones Lang LaSalle is a global financial and professional services firm specializing in commercial real estate services and investment management, with offices in 70 countries serving the real estate needs of a broad list of clients. It produces an annual Life Sciences Cluster Report that covers major global markets with a strong or quickly growing life sciences presence. The U.S. section of this year's report once again featured a ranking of metropolitan areas and this year added a ranking scorecard of the 50 U.S. states and the District of Columbia.
Read More

On Open Innovation, e-Zassi holds a key for device firms

March 1, 2013
By Jim Stommen
Like most entrepreneurs, Peter von Dyck can get pretty evangelistic when he starts talking about his newest idea and newest company. But that company, e-Zassi (Fernandina Beach, Florida), is somewhat different than most start-ups. While it's true that companies are built on ideas, e-Zassi is built on the generating of ideas – that is, making it easier and more efficient to get outside ideas flowing into other companies.
Read More

The MDD Interview: In ranking life science clusters, firm focuses on variety of factors

Feb. 28, 2013
By Jim Stommen
Jones Lang LaSalle is a global financial and professional services firm specializing in commercial real estate services and investment management. It produces an annual Life Sciences Cluster Report that covers major global markets with a strong or quickly growing life sciences presence. The U.S. section of this year's report once again featured a ranking of metropolitan areas and this year added ranking scorecard of the 50 U.S. states and the District of Columbia.
Read More

The MDD Interview: 'Three layers of protection' are keys to a safer sport, says Duma

Feb. 21, 2013
By Jim Stommen
Stefan Duma, PhD, is professor and head of the Department of Biomedical Engineering in the College of Engineering at Virginia Tech (Blacksburg, Virginia). The founding director of Virginia Tech's Center for Injury Biomechanics, he is internationally recognized for his studies in injury biomechanics and traumatic brain injury and part of the national debate over how to protect young athletes from concussions.
Read More

The MDD Interview: As season ends, researchers still huddling on concussion studies

Feb. 14, 2013
By Jim Stommen
Stefan Duma, PhD, is professor and head of the Department of Biomedical Engineering in the College of Engineering at Virginia Tech (Blacksburg, Virginia). The founding director of Virginia Tech's Center for Injury Biomechanics, he is internationally recognized for his studies in injury biomechanics and traumatic brain injury and part of the national debate over how to protect young athletes from concussions.
Read More

The MDD Interview: Lombard: Firm's goal is to impact the cost of healthcare overall

Feb. 7, 2013
By Jim Stommen
Dr. Jay Lombard, a neurologist, is the co-founder and chief scientific officer of Genomind (Chalfont, Pennsylvania), a company focused on improving the lives of patients with psychiatric and neurological conditions through biomarker discovery. Lombard has researched and developed several novel therapeutic interventions to treat depression, dementia, and autism.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • Connecting puzzle pieces

    Korsana boosts Alzheimer’s work with reverse merger, $380M financing

    BioWorld Science
    Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing